Latest placebo Stories
TORONTO, May 15, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2
FREDERICK, Md., May 14, 2014 /PRNewswire/ -- BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced drug-free consumer medical devices, today announced more detail on the interim results
WUPPERTAL, Germany and WHITEHOUSE STATION, New Jersey, May 8, 2014 /PRNewswire/ -- AiCuris and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today
"It’s simply magnificent.
A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.
LEXINGTON, Massachusetts, April 30, 2014 /PRNewswire/ -- - OPUS-2, a Phase 3 placebo-controlled study of lifitegrast 5.0%; results presented at
Positive Clinician-Reported Patient Assessments Consistent with Earlier Findings Reported with ADS-5102 EMERYVILLE, Calif., April 30, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc.
Listen Live on Coast to Coast with George Noory as Dr.
-- UCLA Researcher Reports Adjunctive Trimesta was Associated with Reduced Relapse Rate of 47 Percent -- ROCKVILLE, Md., April 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc.
Palm tocotrienols may slow the progression of brain-degenerating white matter lesions MINNEAPOLIS, April 29, 2014 /PRNewswire/ -- While you may know about
- To swell, as grain or wood with water.